A genome-wide positioning systems network algorithm for in silico drug repurposing

Nature Communications

Volumn 10, Issue 1, 2019, Pages

  Cheng, Feixiong ^a,b   Lu, Weiqiang ^c   Liu, Chuang ^d   Fang, Jiansong ^a   Hou, Yuan ^a   Handy, Diane E ^e   Wang, Ruisheng ^e   Zhao, Yuzheng ^f,g   Yang, Yi ^f,g   Huang, Jin ^f   Hill, David E ^h,i   Vidal, Marc ^h,i   Eng, Charis ^a,b,j   Loscalzo, Joseph ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EAST CHINA NORMAL UNIVERSITY   (China)

^d HANGZHOU NORMAL UNIVERSITY   (China)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j TAUSSIG CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LINIFANIB; NICLOSAMIDE; OLAPARIB; OUABAIN; PICTILISIB; REFAMETINIB; SELUMETINIB; VEMURAFENIB; HIF1A PROTEIN, HUMAN; LEO1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTOME;

ALGORITHM; CANCER; DRUG; GENOME; METABOLISM; PROTEIN;

ACUTE MYELOID LEUKEMIA; ALGORITHM; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CELL VIABILITY; CLEAR CELL CARCINOMA; COLONY FORMATION; COLORECTAL CARCINOMA; COMPUTER MODEL; CONTROLLED STUDY; CUTANEOUS MELANOMA; CYSTADENOCARCINOMA; CYTOTOXICITY; DNA SEQUENCE; DOWN REGULATION; DRUG REPOSITIONING; DRUG RESPONSE; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; GENE MUTATION; GENE ONTOLOGY; GENE REGULATORY NETWORK; GENOME-WIDE ASSOCIATION STUDY; GLIOBLASTOMA; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HUMAN CELL; IC50; LUNG ADENOCARCINOMA; MASS SPECTROMETRY; MUTATION RATE; MUTATIONAL LOAD; PANCREAS ADENOCARCINOMA; PHARMACOGENOMICS; PROSTATE ADENOCARCINOMA; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RNA ISOLATION; RNA SEQUENCE; SOMATIC MUTATION; SQUAMOUS CELL LUNG CARCINOMA; STOMACH ADENOCARCINOMA; SURVIVAL ANALYSIS; THYROID PAPILLARY CARCINOMA; UPREGULATION; WESTERN BLOTTING; WHOLE GENOME SEQUENCING; COMPUTER SIMULATION; DRUG EFFECT; FEASIBILITY STUDY; GENETICS; INFORMATION PROCESSING; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PHILOSOPHY; PROCEDURES; PROTEIN ANALYSIS; SYSTEMS BIOLOGY;

STROPHANTHUS GRATUS;

ADENOCARCINOMA OF LUNG; ALGORITHMS; ARRHYTHMIAS, CARDIAC; COMPUTER SIMULATION; DATASETS AS TOPIC; DRUG REPOSITIONING; FEASIBILITY STUDIES; GENE REGULATORY NETWORKS; HEART FAILURE; HOLISTIC HEALTH; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; OUABAIN; PROTEIN INTERACTION MAPS; SYSTEMS BIOLOGY; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 85071178752     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-019-10744-6     Document Type: Article

References (66)

1. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931–945 (2004).
2. Dugger, S. A., Platt, A. & Goldstein, D. B. Drug development in the era of precision medicine. Nat. Rev. Drug Discov. 17, 183–196 (2018).
3. Antman, E. M. & Loscalzo, J. Precision medicine in cardiology. Nat. Rev. Cardiol. 13, 591–602 (2016).
4. Mullard, A. Nine paths to PCSK9 inhibition. Nat. Rev. Drug Discov. 16, 299–301 (2017).
5. Sahni, N. et al. Widespread macromolecular interaction perturbations in human genetic disorders. Cell 161, 647–660 (2015).
6. Jongen-Lavrencic, M. et al. Molecular minimal residual disease in acute myeloid leukemia. N. Engl. J. Med. 378, 1189–1199 (2018).
7. Menche, J. et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science 347, 1257601 (2015).
8. Cheng, F. et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat. Commun. 9, 2691 (2018).
9. Wang, R. S. & Loscalzo, J. Network-based disease module discovery by a novel seed connector algorithm with pathobiological implications. J. Mol. Biol. 430, 2939–2950 (2018).
10. Cheng, F., Kovacs, I. A. & Barabasi, A. L. Network-based prediction of drug combinations. Nat. Commun. 10, 1197 (2019).
11. Rolland, T. et al. A proteome-scale map of the human interactome network. Cell 159, 1212–1226 (2014).
12. Cheng, F. et al. Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol. Biol. Evol. 31, 2156–2169 (2014).
13. Leiserson, M. D. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47, 106–114 (2015).
14. Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10, 1108–1115 (2013).
15. Ghiassian, S. D., Menche, J. & Barabasi, A. L. A DIseAse MOdule Detection (DIAMOnD) algorithm derived from a systematic analysis of connectivity patterns of disease proteins in the human interactome. PLoS Comput. Biol. 11, e1004120 (2015).
16. Futreal, P. A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177–183 (2004).
17. Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955–D961 (2012).
18. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
19. Bollag, G. et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 11, 873–886 (2012).
20. Lim, H. Y. et al. Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma. Clin. Cancer Res. 24, 4650–4661 (2018).
21. Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381 (2014).
22. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
23. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006).
24. Zhang, J. et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am. J. Pathol. 170, 366–376 (2007).
25. Siddiqui, N. & Sonenberg, N. Signalling to eIF4E in cancer. Biochem. Soc. Trans. 43, 763–772 (2015).
26. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721–732 (2003).
27. Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
28. Zhao, Y. et al. SoNar, a highly responsive NAD+/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell Metab. 21, 777–789 (2015).
29. Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
30. DeNicola, G. M. et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat. Genet. 47, 1475–1481 (2015).
31. Chong, P. S. et al. LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia. Cancer Res. 74, 3043–3053 (2014).
32. Meyer, M. J. et al. Interactome INSIDER: a structural interactome browser for genomic studies. Nat. Methods 15, 107–114 (2018).
33. Cheng, F., Zhao, J., Fooksa, M. & Zhao, Z. A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. J. Am. Med. Inform. Assoc. 23, 681–691 (2016).
34. Pongrakhananon, V., Chunhacha, P. & Chanvorachote, P. Ouabain suppresses the migratory behavior of lung cancer cells. PLoS ONE 8, e68623 (2013).
35. Liu, N. et al. Inhibition of cell migration by ouabain in the A549 human lung cancer cell line. Oncol. Lett. 6, 475–479 (2013).
36. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014).
37. Zhu, F. et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40, D1128–D1136 (2012).
38. Hernandez-Boussard, T. et al. The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res. 36, D913–D918 (2008).
39. Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107 (2012).
40. Liu, T. Q., Lin, Y. M., Wen, X., Jorissen, R. N. & Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35, D198–D201 (2007).
41. Pawson, A. J. et al. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 42, D1098–D1106 (2014).
42. Apweiler, R. et al. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res. 32, D115–D119 (2004).
43. Luck, K. et al. A reference map of the human protein interactome. Preprint at bioRxiv 10.1101/605451 (2019).
44. Cheng, F., Jia, P., Wang, Q. & Zhao, Z. Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget 5, 3697–3710 (2014).
45. Peri, S. et al. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 32, D497–D501 (2004).
46. Newman, R. H. et al. Construction of human activity-based phosphorylation networks. Mol. Syst. Biol. 9, 655 (2013).
47. Hu, J. et al. PhosphoNetworks: a database for human phosphorylation networks. Bioinformatics 30, 141–142 (2014).
48. Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–D520 (2015).
49. Lu, C. T. et al. DbPTM 3.0: an informative resource for investigating substrate site specificity and functional association of protein post-translational modifications. Nucleic Acids Res. 41, D295–D305 (2013).
50. Dinkel, H. et al. Phospho.ELM: a database of phosphorylation sites–update 2011. Nucleic Acids Res. 39, D261–D267 (2011).
51. Chatr-Aryamontri, A. et al. The BioGRID interaction database: 2015 update. Nucleic Acids Res. 43, D470–D478 (2015).
52. Cowley, M. J. et al. PINA v2.0: mining interactome modules. Nucleic Acids Res. 40, D862–D865 (2012).
53. Licata, L. et al. MINT, the molecular interaction database: 2012 update. Nucleic Acids Res. 40, D857–D861 (2012).
54. Orchard, S. et al. The MIntAct project–IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 42, D358–D363 (2014).
55. Breuer, K. et al. InnateDB: systems biology of innate immunity and beyond–recent updates and continuing curation. Nucleic Acids Res. 41, D1228–D1233 (2013).
56. Meyer, M. J., Das, J., Wang, X. & Yu, H. INstruct: a database of high-quality 3D structurally resolved protein interactome networks. Bioinformatics 29, 1577–1579 (2013).
57. Fazekas, D. et al. SignaLink 2—a signaling pathway resource with multi-layered regulatory networks. BMC Syst. Biol. 7, 7 (2013).
58. Coordinators, N. R. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 44, D7–D19 (2016).
59. Chang, C.-C. LIBSVM: a library for support vector machines. ACM Trans. Intel. Syst. Technol. 2, 1–27 (2011).
60. Cheng, F. et al. Systems biology-based investigation of cellular antiviral drug targets identified by gene-trap insertional mutagenesis. PLoS Comput. Biol. 12, e1005074 (2016).
61. Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091–1093 (2009).
62. Jiang, X. et al. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. JCI Insight 3, e98921 (2018).
63. Xia, X. & Kung, A. L. Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. Genome Biol. 10, R113 (2009).
64. Bovolenta, L. A., Acencio, M. L. & Lemke, N. HTRIdb: an open-access database for experimentally verified human transcriptional regulation interactions. BMC Genom. 13, 405 (2012).
65. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
66. Okayama, H. et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 72, 100–111 (2012).